Shanghai Henlius Biotech

• A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  Phase 2/3, Not yet recruiting, 1,438 people, 8 Oct 2026

• NCT07739758

  Collaborator, Phase 3, Recruiting, 442 people, 31 Jul 2026

• NCT07716046

  Collaborator, Phase 2, Not yet recruiting, 240 people, 21 Jul 2026

• NCT07480681

  Phase 1, Not yet recruiting, 138 people, 18 Mar 2026

• NCT07318883

  Phase 2/3, Not yet recruiting, 720 people, 6 Jan 2026

• NCT07257575

  Collaborator, Phase 2, Active, not recruiting, 138 people, 2 Dec 2025

• NCT06532006

  Phase 3, Recruiting, 550 people, 1 Aug 2024

• NCT05468489

  Phase 3, Active, not recruiting, 200 people, 21 Jul 2022

• NCT05354700

  Phase 2, Status unknown, 20 people, 29 Apr 2022

• NCT05353257

  Phase 3, Active, not recruiting, 511 people, 29 Apr 2022

• NCT05246982

  Phase 2, Status unknown, 40 people, 18 Feb 2022

• NCT05221658

  Phase 2, Status unknown, 60 people, 3 Feb 2022

• NCT05215925

  Phase 2, Status unknown, 60 people, 31 Jan 2022

• NCT04965220

  Phase 1, Status unknown, 220 people, 16 Jul 2021

• NCT04908813

  Phase 2, Status unknown, 150 people, 1 Jun 2021

• NCT04806945

  Phase 3, Withdrawn, 0 people, 19 Mar 2021

• NCT04465734

  Phase 3, Withdrawn, 0 people, 10 Jul 2020

• NCT04301739

  Phase 3, Not yet recruiting, 522 people, 10 Mar 2020

• NCT04297995

  Phase 2, Status unknown, 131 people, 6 Mar 2020

• NCT04063163

  Phase 3, Completed, 585 people, 21 Aug 2019

Sources: clinicaltrials.gov